3rd Quarter - Termination

ACCENDRA HEALTH INC. for ACCENDRA HEALTH INC.

Firm
Client
Income
—
Expenses
$200,000
Expense method
A: Lobbying Disclosure Act definitions
Terminated
Sep 30, 2026

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Issues related to access to home medical equipment and related reimbursement (i.e., "Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services [DIABETES] Act" (S. 4037) and "DMEPOS Relief Act of 2025" [H.R. 2005, S. 2951]; and competitive bidding, "Supplemental Oxygen Access Reform [SOAR] Act of 2025" [H.R. 2902, S. 1406]); "DME Scammer Prevention (H.R. 8871)"; promoting electronic prescribing platforms; and diabetes management and related durable medical equipment reimbursement channels.

LobbyistCovered position, as disclosed
FAITH A. CRISTOL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1406 (119th), H.R. 2005 (119th), S. 4037 (119th), H.R. 2902 (119th), H.R. 8871 (119th), S. 2951 (119th)

Budget/Appropriations BUD

FY 2027 Appropriations.

LobbyistCovered position, as disclosed
FAITH A. CRISTOL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Issues related to patient access to home medical equipment and related reimbursement.

LobbyistCovered position, as disclosed
FAITH A. CRISTOL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.